Publications by authors named "B Powers"
Background: Approximately half of patients with localised, high-risk soft tissue sarcoma of the extremity develop metastases. We aimed to assess whether the addition of pembrolizumab to preoperative radiotherapy and surgery would improve disease-free survival.
Methods: We completed an open-label, randomised clinical trial in patients with grade 2 or 3, stage III undifferentiated pleomorphic sarcoma or dedifferentiated or pleomorphic liposarcoma of the extremity and limb girdle.
Introduction: The need to train oncologists to address the complexities of the aging population has been a focus of educational initiatives and strategies since the 1980s. However, large gaps in the dissemination and implementation of geriatric oncology curricula are still present. Currently, few resources exist for oncology training programs to implement a formal geriatric oncology curriculum.
View Article and Find Full Text PDFArticle Synopsis
- - Alzheimer's disease is characterized by impaired memory formation, which relies on the ability of neurons to rapidly transcribe genes, a process influenced by the state of RNA polymerase II (RNAP2).
- - When neurons are stimulated, RNAP2 is released from a paused state, allowing it to produce messenger RNA (mRNA), with this release regulated by a complex involving positive transcription elongation factor b (P-TEFb) and HEXIM1.
- - The study shows that the regulation of P-TEFb by HEXIM1 plays a crucial role in the transcription of genes in neurons, especially in response to stimulation, highlighting its importance for memory-related functions and synaptic plasticity in the context of Alzheimer's disease. *
Article Synopsis
- Dual inhibition using ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) was tested on patients with desmoid tumors in a phase II clinical trial to assess efficacy and safety in treating these rare solid tumors.
- The study involved 16 patients, with an overall response rate (ORR) of 18.8%, and a clinical benefit rate (CBR) of 62.5%, indicating decent stability and response to treatment over an average of 19.4 months of progression-free survival (PFS).
- Adverse events were common, with fatigue, nausea, and hypothyroidism reported, highlighting the need for careful monitoring during treatment.